肝硬化门静脉高压症临床治疗

Clinical study on treatment of liver cirrhosis with portal hypertension

目的:探讨肝硬化门静脉高压症的临床治疗方法。方法:收治肝硬化门静脉高压症患者40例,将其均分为对照组与观察组,对对照组实施常规的治疗,观察组在常规治疗的基础上,加用缬沙坦治疗,在患者的治疗前后应用彩色多普勒超声仪对其门静脉及脾静脉的流速与内径进行检测,并在整个治疗过程中,对患者的心率、血压、肝肾功能、血常规等予以监测。结果:观察组的门静脉与脾静脉流速、内径与治疗前相比具有明显的变化,并且差异具有统计学意义(P<0.05);患者的心率、血压没有明显的变化,同时患者的肝肾功能、血常规等没有受到明显的损害;而对照组的各项指标都没有明显的变化。结论:将缬沙坦应用于肝硬化门静脉高压症患者的治疗中,能够有效地提升患者的血流速度,降低患者的门静脉压力,并不会对患者的肝肾功能、血常规、心率、血压等产生影响,具有较好的临床治疗效果。

Objective:To explore the clinical treatment of liver cirrhosis with portal hypertension.Methods:40 patients with liver cirrhosis with portal hypertension were selected.They were randomly divided into the control group and the observation group.The control group were treated with routine treatment,and the observation group was treated with valsartan on the basis of conventional therapy.Before and after treatment,the velocity and diameter of portal veins and splenic veins were examined by color Doppler ultrasound.In the whole course of treatment,patients heart rate,blood pressure,liver and kidney function,blood routine were monitoring.Results:In the observation group,compared with before treatment,portal vein and splenic vein flow velocity,diameter had the obvious change,and the difference had statistical significance(P<0.05);The patient's heart rate,blood pressure did not change obviously,the liver and kidney function and blood routine in patients were without apparent damage;in the control group,the indexes of patients had no obvious change.Conclusion:Valsartan used in liver cirrhosis with portal hypertension patients can effectively improve the blood flow velocity of patients and reduce portal pressure of patients,and it has no effect on the liver and kidney function,toutine blood test,heart rate,blood pressure and so on.It has better clinical therapeutic effect.